Post by
subaru1i on Mar 31, 2024 7:49pm
mdjbrown....read between the lines...'launching generic
Epidiolex in the U.S.' That means the submission is already at the FDA level and awaiting approval.
AND.............
LABS mentioned clearly, launching generic Epidiolex in the U.S. and by using SEDDS technology (remember, Trunerox is CBD also) from Avicanna, it distinguishes itself in DELIVERY form as well. A more effective generic than the original!!!
IF the LABS generic form of Epidiolex were to only capture 20% of that market, that's a nifty $200 million in revenues for LABS.
I can't argue with Pidduck, LABS is undervaled ;-)